Overprescription of Short-acting β2 Agonists: Reflections from the SABINA Study in Brazil

Overview

Journal J Bras Pneumol

Specialty Pulmonary Medicine

Date 2024 Feb 29

PMID 38422337

Authors

Martti Anton Antila

Adelmir Souza-Machado

Marcelo Gervilla Gregorio

Alvaro A Cruz

Luciene Angelini

Maarten J H I Beekman

Gilmar Alves Zonzin

Marcelo Fouad Rabahi

Affiliations

Soon will be listed here.

Abstract

Objective: To assess prescription patterns for short-acting b2 agonists (SABAs) and other asthma medications in asthma patients treated by specialists and participating in the SABA use IN Asthma (SABINA) study in Brazil.

Methods: This was an observational, cross-sectional study conducted at five sites in different regions of Brazil. The primary endpoints were to record SABA prescriptions and obtain data on over-the-counter (OTC) SABA purchases at the pharmacy.

Results: Data on 218 asthma patients were analyzed. Of those 218 patients, 80.3% were prescribed SABAs in addition to their maintenance therapy, with a mean of 11.2 SABA canisters in the previous 12 months. Of those patients, 71.4% were prescribed ≥ 3 canisters and 42.2% were prescribed ≥ 10 canisters. None of the patients were prescribed SABA monotherapy. A total of 14.2% of the patients reported purchasing SABAs OTC at a pharmacy without a prescription. Of those, 48.4% purchased ≥ 3 SABA canisters. A fixed-dose combination of an inhaled corticosteroid and a long-acting b2 agonist was prescribed to 95.0% of the patients. In the year before the study visit, 45.0% of the patients received at least one course of oral corticosteroid burst treatment. Asthma was well controlled in 43.1% of the patients, partly controlled in 34.9%, and uncontrolled in 22.0%. Patients reported a mean of 1.1 severe asthma exacerbations, with 49.1% experiencing 1 or more severe exacerbations.

Conclusions: Overprescription and OTC purchases of SABAs are common in Brazil, possibly leading to the need for courses of oral corticosteroids. The health care community should collaborate to implement evidence-based recommendations and promote health education to improve asthma management in Brazil.

References

Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K . Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991; 325(6):388-92. DOI: 10.1056/NEJM199108083250603. View

Bateman E, Reddel H, OByrne P, Barnes P, Zhong N, Keen C . As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378(20):1877-1887. DOI: 10.1056/NEJMoa1715275. View

OByrne P, FitzGerald J, Bateman E, Barnes P, Zhong N, Keen C . Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018; 378(20):1865-1876. DOI: 10.1056/NEJMoa1715274. View

Nannini L, Luhning S, Rojas R, Antunez J, Miguel Reyes J, Cano Salas C . Position statement: asthma in Latin America. IS short-acting beta-2 agonist helping or compromising asthma management?. J Asthma. 2020; 58(8):991-994. DOI: 10.1080/02770903.2020.1777563. View

Cabrera C, Nan C, Lindarck N, Beekman M, Arnetorp S, van der Valk R . SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β-agonist use in asthma. Eur Respir J. 2019; 55(2). DOI: 10.1183/13993003.01858-2019. View

Cancado J, Penha M, Gupta S, Li V, Julian G, de Sa Moreira E . Respira project: Humanistic and economic burden of asthma in Brazil. J Asthma. 2018; 56(3):244-251. DOI: 10.1080/02770903.2018.1445267. View

Neffen H, Moraes F, Viana K, Di Boscio V, Levy G, Vieira C . Asthma severity in four countries of Latin America. BMC Pulm Med. 2019; 19(1):123. PMC: 6617663. DOI: 10.1186/s12890-019-0871-1. View

Comaru T, Pitrez P, Friedrich F, Silveira V, Pinto L . Free asthma medications reduces hospital admissions in Brazil (Free asthma drugs reduces hospitalizations in Brazil). Respir Med. 2016; 121:21-25. DOI: 10.1016/j.rmed.2016.10.008. View

Al Zaabi A, Busaidi N, Al Mutairy S, Yorgancioglu A, Aksu K, Al-Jahdali H . Overprescription of short-acting β-agonists is associated with poor asthma symptom control: results from five Middle Eastern countries included in the SABINA International (III) study. Expert Rev Respir Med. 2022; 16(7):833-847. DOI: 10.1080/17476348.2022.2099841. View

10.

Khattab A, Madkour A, Ambaram A, Smith C, Muhwa C, Mecha J . Over-prescription of short-acting β-agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study. Curr Med Res Opin. 2022; 38(11):1983-1995. DOI: 10.1080/03007995.2022.2100649. View

11.

Jenkins C, Bateman E, Sears M, OByrne P . What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?. Respirology. 2020; 25(8):804-815. DOI: 10.1111/resp.13804. View

12.

Kuna P, Peters M, Manjra A, Jorup C, Naya I, Martinez-Jimenez N . Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007; 61(5):725-36. PMC: 1920547. DOI: 10.1111/j.1742-1241.2007.01338.x. View

13.

Azzi E, Kritikos V, Peters M, Price D, Srour P, Cvetkovski B . Understanding reliever overuse in patients purchasing over-the-counter short-acting beta agonists: an Australian community pharmacy-based survey. BMJ Open. 2019; 9(8):e028995. PMC: 6701672. DOI: 10.1136/bmjopen-2019-028995. View

14.

Bateman E, Price D, Wang H, Khattab A, Schonffeldt P, Catanzariti A . Short-acting β-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J. 2021; 59(5). PMC: 9068976. DOI: 10.1183/13993003.01402-2021. View

15.

Henry D, Sutherland D, Francis L . The use of non-prescription salbutamol inhalers by asthmatic patients in the Hunter Valley, New South Wales. Newcastle Retail Pharmacy Research Group. Med J Aust. 1989; 150(8):445-9. View

16.

Alith M, Gazzotti M, Nascimento O, Jardim J . Impact of asthma control on different age groups in five Latin American countries. World Allergy Organ J. 2020; 13(4):100113. PMC: 7118313. DOI: 10.1016/j.waojou.2020.100113. View

17.

Reddel H, Ampon R, Sawyer S, Peters M . Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017; 7(9):e016688. PMC: 5623555. DOI: 10.1136/bmjopen-2017-016688. View

18.

Blakeston S, Harper G, Zabala Mancebo J . Identifying the drivers of patients' reliance on short-acting β2-agonists in asthma. J Asthma. 2020; 58(8):1094-1101. DOI: 10.1080/02770903.2020.1761382. View

19.

Gibson P, Henry D, Francis L, Cruickshank D, Dupen F, Higginbotham N . Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ. 1993; 306(6891):1514-8. PMC: 1677936. DOI: 10.1136/bmj.306.6891.1514. View

20.

Reddel H, FitzGerald J, Bateman E, Bacharier L, Becker A, Brusselle G . GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019; 53(6). DOI: 10.1183/13993003.01046-2019. View